Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human MDM4-binding Protein Antibodies:
anti-Rat (Rattus) MDM4-binding Protein Antibodies:
anti-Mouse (Murine) MDM4-binding Protein Antibodies:
Go to our pre-filtered search.
Human Polyclonal MDM4-binding Protein Primary Antibody for IP, WB - ABIN151988
Patton, Mayo, Singhi, Gudkov, Stark, Jackson: Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. in Cancer research 2006
Show all 32 Pubmed References
Mouse (Murine) Monoclonal MDM4-binding Protein Primary Antibody for IP, ELISA - ABIN3201009
Chen, Gilkes, Pan, Lane, Chen: ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. in The EMBO journal 2005
Show all 3 Pubmed References
Human Monoclonal MDM4-binding Protein Primary Antibody for ICC, IHC - ABIN969282
Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... in Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 3 Pubmed References
Human Polyclonal MDM4-binding Protein Primary Antibody for IF, WB - ABIN517808
Jacob, OBrien, Singh, Comiskey, Littleton, Mohammad, Gladman, Widmann, Jeyaraj, Bolinger, Anderson, Barkauskas, Boris-Lawrie, Chandler: Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma. in Neoplasia (New York, N.Y.) 2013
Cow (Bovine) Polyclonal MDM4-binding Protein Primary Antibody for WB - ABIN2792185
Danovi, Meulmeester, Pasini, Migliorini, Capra, Frenk, de Graaf, Francoz, Gasparini, Gobbi, Helin, Pelicci, Jochemsen, Marine: Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. in Molecular and cellular biology 2004
Show all 2 Pubmed References
Human Monoclonal MDM4-binding Protein Primary Antibody for IF, IHC - ABIN2670914
Mancini, Pieroni, Monteleone, Lucà, Fici, Luca, Urbani, Xiong, Soddu, Masetti, Lozano, Pontecorvi, Moretti: MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. in Oncogene 2015
Human Polyclonal MDM4-binding Protein Primary Antibody for WB - ABIN2442622
Elgohary, Pellegrino, Neumann, Elzawahry, Saber, Zeeneldin, Geffers, Ehemann, Schemmer, Schirmacher, Longerich: Protumorigenic role of Timeless in hepatocellular carcinoma. in International journal of oncology 2014
MDM4 rs4245739 A > C polymorphism appears to be associated with decreased cancer risk
analyses indicated that rs4245739 polymorphism in the MDM4 gene may play an important role in the etiology of cancer
analysis of linear and stapled peptides comprising 6-Me-tryptophan provides mechanistic insight into dual Mdm2 (show MDM2 Antibodies)/Mdm4 antagonism and confirms L98 of Mdm4 as a mutable steric gate. The results also highlight a possible role of the flexible hinge region in determining Mdm2 (show MDM2 Antibodies)/Mdm4 plasticity
we have herein demonstrated that ERalpha (show ESR1 Antibodies) expression associates with MDM4 and MDM2 (show MDM2 Antibodies) gene expression in primary breast invasive carcinoma samples
It is now clear that functional p53 (show TP53 Antibodies) is critical to protect the genome from alterations that lead to tumorigenesis. The current understanding of the multiple ways p53 (show TP53 Antibodies) contributes to genome stability and how two of its negative regulators, Mdm2 (show MDM2 Antibodies) and Mdmx, induce genome instability will be described. [review]
results revealed an allosteric ligand-binding mechanism of the N-terminal domain of MdmX in which the ligand initially interacts with a compact core, followed by augmenting intermolecular interactions with intrinsic flexible regions
Complex alterations of HDM4 proteins, which are critical regulators of cell cycle progression, are frequent defects in AML (show RUNX1 Antibodies) and HG-MDS (show PAFAH1B1 Antibodies) cases. The overall rates of detection of HDM4 expression in the present study, 92% in AML (show RUNX1 Antibodies) and 52% in MDS (show PAFAH1B1 Antibodies), respectively, indicate that HDM4 is a potential therapeutic target in patients with these diseases.
MDM4 rs1380576 G variant is associated with gastric cancer.
These results demonstrate that cisplatin-mediated p53 (show TP53 Antibodies)(V172F) mutation regulates p53 (show TP53 Antibodies) stability at the normothermic temperature, but it is the increased recruitment of MDM4 by the homomeric or heteromeric mutant p53 (show TP53 Antibodies)(V172F) complex that inhibits p53 (show TP53 Antibodies)-dependent transactivation. This represents a novel cellular mechanism of p53 (show TP53 Antibodies) inhibition, and, thereby, induction of cisplatin resistance
MDM4 protein is frequently abundant in the context of mutant p53 (show TP53 Antibodies) in basal-like breast cancer (BC) samples. MDM4 plays a critical role in the proliferation of these BC cells. MDM4 is crucial for the establishment and progression of tumours.
Data indicate that knockdown of the Mdm2 (show MDM2 Antibodies) and Mdm4 caused dramatic accumulation of mutant p53 protein (show TP53 Antibodies).
crystal structure of N-terminal domain of Mdmx bound to 15-residue p53 (show TP53 Antibodies) peptide was determined; structure reveals that although principle features of Mdm2 (show MDM2 Antibodies)-p53 (show TP53 Antibodies) interaction are preserved, the Mdmx hydrophobic cleft on which the p53 (show TP53 Antibodies) peptide binds is altered
The p53 (show TP53 Antibodies)-null mice with the highest level of Mdm4 tended to have multiple tumours. Mdm4 transgenic mice in various genetic backgrounds shows synergy in tumour development in vivo. Mdm4 may thus serve as a therapeutic target in cancers.
These findings suggest that Mdm2 (show MDM2 Antibodies) splice isoforms may play critical roles in the regulatory loop of p53 (show TP53 Antibodies)/Mdm2 (show MDM2 Antibodies)-Mdm4 via a RING domain-mediated biochemical mechanism.
both MDM2 (show MDM2 Antibodies) and MDMX deletion-caused pancreatic defects are completely rescued by loss of p53 (show TP53 Antibodies), verifying the crucial role of the MDM2 (show MDM2 Antibodies) and/or MDMX in regulating p53 (show TP53 Antibodies) in a spatio-temporal manner during the development, functional maintenance, and related disease progress of endocrine pancreas.
we failed to detect any increase in p53 (show TP53 Antibodies) level in mutant oocytes, nor any other apoptotic marker, introgression of this targeted invalidation in p53 (show TP53 Antibodies)-/- mice restored the fertility of females. This study is the first to show that Mdm2 (show MDM2 Antibodies), but not Mdm4, has a critical role in oocyte survival and would be involved in premature ovarian insufficiency phenotype.
Data show that the Mdm4-p73 (show ARHGAP24 Antibodies) axis cannot override the dominant role of p53 (show TP53 Antibodies) in development and tumorigenesis and that Mdm4 and p73 (show ARHGAP24 Antibodies) interaction during development and tumorigenesis suggests new insight into the role of p53 (show TP53 Antibodies) family members.
MDM4/HIPK2 (show HIPK2 Antibodies)/p53 (show TP53 Antibodies) cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.
MDMx degradation associated with neuronal death occurs via caspase (show CASP3 Antibodies) activation in neurons, and that the progressive loss of MDMx protein represents a potential mechanism of Abeta (show APP Antibodies)-induced neuronal death during disease progression in AD
our results show MDM4-MDM2 (show MDM2 Antibodies)/p53 (show TP53 Antibodies)-IGF1R (show IGF1R Antibodies) as an original regulatory mechanism for CNS regeneration
Increased Mdm4-S mRNA levels might correlate with more aggressive cancers without encoding significant amounts of a potential oncoprotein.
results reveal a novel p53 (show TP53 Antibodies)- and Mdm2 (show MDM2 Antibodies)-independent oncogenic function of Mdmx that provides new insight into the many cancers that overexpress Mdmx.
This gene encodes a nuclear protein that contains a p53 binding domain at the N-terminus and a RING finger domain at the C-terminus, and shows structural similarity to p53-binding protein MDM2. Both proteins bind the p53 tumor suppressor protein and inhibit its activity, and have been shown to be overexpressed in a variety of human cancers. However, unlike MDM2 which degrades p53, this protein inhibits p53 by binding its transcriptional activation domain. This protein also interacts with MDM2 protein via the RING finger domain, and inhibits the latter's degradation. So this protein can reverse MDM2-targeted degradation of p53, while maintaining suppression of p53 transactivation and apoptotic functions. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene.
double minute 4 protein
, mdm2-like p53-binding protein
, p53-binding protein Mdm4
, protein Mdm4
, MDM4-related protein 1
, double minute 4, human homolog of; p53-binding protein
, protein Mdmx
, Mdm4, transformed 3T3 cell double minute 4, p53 binding protein
, double minute 4 homolog
, transformed mouse 3T3 cell double minute 4